• Dextrose (D-Glucose) in Tumor Immunometabolism

  2026-08-12

  Dextrose and D-glucose are not merely carbon sources: they are experimental variables that connect glycolysis, hypoxia, and immune-cell function. This guide translates tumor immunometabolism findings into practical assay design, reagent handling, and interpretation strategies.

• Live-Dead Bacterial Staining Kit Guide

  2026-08-12

  Learn how Live-Dead Bacterial Staining Kit SKU K2239 supports interpretable bacterial viability assays in antimicrobial, nanomaterial, and infection-model workflows. This scenario-based guide explains dye biology, controls, protocol standardization, data interpretation, and practical product selection.

• Anti-ROR1 Antibody Workflow for Translational Assays

  2026-08-11

  Build reproducible ROR1 binding, flow cytometry, and functional assay workflows with Zilovertamab, while keeping product-validated facts separate from optimization starting points. A mechanistic liver-injury study also shows how orthogonal mitochondrial, oxidative-stress, and pathway readouts can strengthen interpretation without implying untested cross-disease efficacy.

• Phosphatase Inhibitor Cocktail 2 in Chemoproteomics

  2026-08-11

  Phosphatase Inhibitor Cocktail 2 protects phosphorylation-dependent measurements from pre-analytic distortion. This guide connects phosphatase control with temperature-aware chemical proteomics and practical assay design.

• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-08-10

  RG108 is a non-covalent DNA methyltransferase inhibitor for testing how methylation changes reshape gene expression in human cell models. This workflow separates biochemical potency from cellular response, combines methylation and phenotype readouts, and adapts assay-design lessons from recent mechanistic research without overstating antiviral or therapeutic applications.

• EZ Cap™ Cas9 mRNA (m1Ψ) and Editing Control

  2026-08-09

  EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for controlled Cas9 expression. This article connects RNA architecture with temporal exposure, assay interpretation, and CRISPR-Cas9 precision decisions.

• LY2603618: Chk1 Inhibitor Research Guide

  2026-08-08

  LY2603618 is a selective Chk1 inhibitor that blocks ATP-site kinase activity and supports studies of DNA damage response, G2/M checkpoint control, and chemotherapy sensitization. Product information reports activity in lung and colon cancer models, while a 2024 HGSOC study provides a biomarker framework for interpreting CHK1 dependence.

• Annexin V-Cy5/DAPI Apoptosis Kit Guide

  2026-08-07

  The Annexin V-Cy5/DAPI Apoptosis Kit combines phosphatidylserine detection with DAPI membrane-integrity staining for rapid apoptosis and necrosis differentiation. The K2255 apoptosis detection kit supports fluorescence microscopy and flow cytometry within a product-reported 10–20-minute staining workflow.

• EZ Cap™ Cas9 mRNA (m1Ψ): Redefining Immune-Modulated Genome

  2026-08-07

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) leverages Cap1 structure and m1Ψ modification to optimize genome editing specificity and efficiency. This article uniquely analyzes immune modulation and assay design, bridging molecular engineering with translational research.

• Transforming mRNA Vaccine Design: Mechanisms and Strategic T

  2026-08-06

  This article bridges mechanistic insight and translational strategy for researchers advancing mRNA nanovaccine therapeutics, focusing on optimized ARCA-capped mRNA synthesis. It contextualizes the HyperScribe™ Co-transcription mRNA Synthesis Kit Plus (ARCA, T7) within the latest immunotherapy breakthroughs, especially in hepatocellular carcinoma, and provides actionable workflow guidance, protocol parameters, and forward-looking perspectives.

• Oxaliplatin: Platinum-Based Chemotherapeutic Agent Profile

  2026-08-06

  Oxaliplatin is a platinum-based chemotherapeutic agent with proven efficacy in metastatic colorectal cancer therapy. It induces apoptosis via DNA adduct formation and is widely used in both preclinical and clinical oncology research. Its unique mechanism differentiates it from other platinum compounds, notably with distinct resistance patterns.

• Liproxstatin-1: Precision Ferroptosis Inhibitor in Research

  2026-08-05

  Liproxstatin-1 empowers researchers to dissect ferroptosis with nanomolar precision and robust protection in GPX4-deficient and oxidative stress models. Discover protocol-driven insights and troubleshooting strategies for maximizing its impact in organ injury, neurodegeneration, and beyond.

• Non-Invasive Cephalopod Sex Genotyping via qPCR: A New Stand

  2026-08-05

  Rubino et al. present a robust, non-invasive quantitative PCR method for sex genotyping in diverse cephalopod species, relying on skin swabs and dosage analysis of Z-chromosome content. This approach enables accurate, early-life sex determination, supporting sustainable research and aquaculture management.

• Epoxomicin in PQC: Precision Tools for ER Stress and Transla

  2026-08-04

  This article explores the mechanistic underpinnings and translational potential of Epoxomicin as a selective, irreversible proteasome inhibitor. It connects recent findings on ER stress, protein quality control, and the role of N-recognins UBR1/UBR2, guiding researchers on designing robust ubiquitin-proteasome pathway studies. Strategic protocol advice and industry context elevate this piece beyond standard product overviews.

• BET Inhibition Alters HPV-16+ HNSCC Gene Expression and Cell

  2026-08-04

  This study explores how BET protein inhibition impacts gene expression and cell cycle regulation in HPV-16-associated head and neck squamous cell carcinoma (HNSCC). The findings reveal heterogeneous transcriptional responses to BET inhibition, including downregulation of viral oncogenes and cell cycle arrest, offering insights for targeted epigenetics research in cancer biology.

546 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page